Acusphere Announces FDA Acceptance Of Imagify? NDA For Detection Of Coronary Artery Disease
Jul 4th 2008Drug InformationCardiovascular
Acusphere, Inc. (NASDAQ: ACUS) announced that the New Drug Application (NDA) for approval to market its lead product candidate, Imagify? (Perflubutane Polymer Microspheres for Injectable Suspension), has been accepted for review by the U.S. Food & Drug Administration (FDA). Imagify is an ultrasound imaging agent for the detection of coronary artery disease, the leading cause of death in the United States.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
